ENHERTU® (Fam-Trastuzumab Deruxtecan-Nxki) Approved in the US for Two New Indications for Patients with HER2-Positive Early Breast Cancer

Key Takeaways

• ENHERTU approved for neoadjuvant HER2‑positive early breast cancer.
• ENHERTU approved for adjuvant use after surgery with residual disease.
• DESTINY‑Breast11 showed 67.3% pCR, 11% improvement vs chemotherapy.
• DESTINY‑Breast05 cut invasive disease recurrence risk by 53% versus T‑DM1.
• AstraZeneca will pay Daiichi Sankyo $155 million milestone for approvals.

Pulse Analysis

HER2‑positive breast cancer accounts for roughly 20% of all cases and has long been treated with trastuzumab‑based regimens that improve survival but leave a sizable recurrence risk. Early‑stage disease, especially stage II‑III, presents a therapeutic window where intensified therapy can eradicate micrometastatic cells before they seed metastases. \n\nThe DESTINY‑Breast11 and DESTINY‑Breast05 Phase III trials provide the clinical backbone for the FDA’s decision.

3% rate of dose‑dense anthracycline‑cyclophosphamide followed by standard HER2‑targeted therapy, a statistically significant gain that suggests higher rates of breast‑conserving surgery and lower residual disease. The adjuvant study demonstrated a 53% relative reduction in invasive disease‑free events versus T‑DM1, translating to a three‑year IDFS advantage of nearly 9 percentage points.

\n\nFrom a market perspective, the dual approvals broaden ENHERTU’s addressable population from metastatic to early‑stage patients, potentially adding millions of treatment courses in the United States alone. The $155 million milestone underscores the commercial stakes for AstraZeneca and Daiichi Sankyo, while inclusion in NCCN guidelines as a Category 1 recommendation may accelerate uptake. Competitors will need to demonstrate comparable efficacy or safety to retain market share, and ongoing trials in other early‑stage HER2 contexts could further cement ENHERTU’s role as a cornerstone of HER2‑targeted therapy.